Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

522 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimizing radiation use during fluoroscopic procedures: proceedings from a multidisciplinary consensus panel.
Duncan JR, Balter S, Becker GJ, Brady J, Brink JA, Bulas D, Chatfield MB, Choi S, Connolly BL, Dixon RG, Gray JE, Kee ST, Miller DL, Robinson DW, Sands MJ, Schauer DA, Steele JR, Street M, Thornton RH, Wise RA. Duncan JR, et al. Among authors: gray je. J Vasc Interv Radiol. 2011 Apr;22(4):425-9. doi: 10.1016/j.jvir.2010.12.008. J Vasc Interv Radiol. 2011. PMID: 21463753 No abstract available.
Optimal resources for the examination and endovascular treatment of the peripheral and visceral vascular systems. AHA Intercouncil Report on Peripheral and Visceral Angiographic and Interventional Laboratories.
Cardella JF, Casarella WJ, DeWeese JA, Dorros GM, Gray JE, Katzen BT, Laragh JH, Levin DC, Marx VM, Nickoloff EL, Pentecost MJ, Roubin GS, Martin EC; Intersociety Commission for Heart Disease Resources, American Heart Association. Cardella JF, et al. Among authors: gray je. J Vasc Interv Radiol. 2003 Sep;14(9 Pt 2):S517-30. doi: 10.1016/s1051-0443(07)61268-8. J Vasc Interv Radiol. 2003. PMID: 14514866 No abstract available.
S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma.
Tsao AS, Hsieh MH, Koczywas M, Tu J, Riess J, Tanvetyanon T, Ma BT, Zhao YQ, Redman MW, Edelman MJ, Gandara DR, Gray JE, Kelly KL. Tsao AS, et al. Among authors: gray je. JTO Clin Res Rep. 2024 Oct 16;5(12):100738. doi: 10.1016/j.jtocrr.2024.100738. eCollection 2024 Dec. JTO Clin Res Rep. 2024. PMID: 39619274 Free PMC article.
Rethinking how mobile units can catalyze progress on lung cancer screening: a scoping review of what we have learned.
Karanth SD, Divaker J, Blair M, Gray JE, Hochhegger B, Kobetz E, Machuca T, Rackauskas M, Yang D, Rodriguez E, Schabath MB, Yoon HS, Braithwaite D. Karanth SD, et al. Among authors: gray je. J Thorac Dis. 2024 Oct 31;16(10):7143-7154. doi: 10.21037/jtd-24-846. Epub 2024 Oct 30. J Thorac Dis. 2024. PMID: 39552879 Free PMC article. Review.
The Phase 3 KEYLYNK-006 Study of Pembrolizumab plus Olaparib versus Pembrolizumab plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Gray JE, Schenker M, Nahit Şendur MA, Leonova V, Kowalski D, Kato T, Orlova R, Chih-Hsin Yang J, Langleben A, Pilz A, Ungureanu A, Mak MP, Flavia De Angelis, Aggarwal H, Zimmer Z, Zhao B, Shamoun M, Kim TM. Gray JE, et al. J Thorac Oncol. 2024 Nov 7:S1556-0864(24)02435-3. doi: 10.1016/j.jtho.2024.10.026. Online ahead of print. J Thorac Oncol. 2024. PMID: 39521434
Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929.
Karim NA, Miao J, Reckamp KL, Gay CM, Byers LA, Zhao YQ, Redman MW, Carrizosa DR, Wang WL, Petty WJ, Mehta K, Faller BA, Agamah ES, Kasbari SS, Malisetti RK, Kumar A, Schallenkamp J, Alluri KC, Gray JE, Kelly K. Karim NA, et al. Among authors: gray je. J Thorac Oncol. 2024 Nov 4:S1556-0864(24)02431-6. doi: 10.1016/j.jtho.2024.10.021. Online ahead of print. J Thorac Oncol. 2024. PMID: 39505259
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous Non-Small-Cell Lung Cancer That Responded to First-Line Pembrolizumab Plus Chemotherapy.
Hochmair M, Schenker M, Dols MC, Kim TM, Ozyilkan O, Smagina M, Viktoriya L, Kato T, Fedenko A, De Angelis F, Rittmeyer A, Gray JE, Greystoke A, Aggarwal H, Huang Q, Zhao B, Lara-Guerra H, Nadal E. Hochmair M, et al. Among authors: gray je. J Thorac Oncol. 2024 Oct 28:S1556-0864(24)02420-1. doi: 10.1016/j.jtho.2024.10.012. Online ahead of print. J Thorac Oncol. 2024. PMID: 39477187
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP… See abstract for full author list ➔ Skoulidis F, et al. Among authors: gray je. Nature. 2024 Nov;635(8038):462-471. doi: 10.1038/s41586-024-07943-7. Epub 2024 Oct 9. Nature. 2024. PMID: 39385035 Free PMC article.
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).
Le X, Patel JD, Shum E, Baik C, Sanborn RE, Shu CA, Kim C, Fidler MJ, Hall R, Elamin YY, Tu J, Blumenschein G, Zhang J, Gibbons D, Gay C, Mohindra NA, Chae Y, Boumber Y, Sabari J, Santana-Davila R, Rogosin S, Herzberg B, Creelan B, Pellini B, Tanvetyanon T, Heeke S, Hernandez M, Gray JE, Saltos A, Heymach JV. Le X, et al. Among authors: gray je. J Clin Oncol. 2024 Oct 8:JCO2400533. doi: 10.1200/JCO.24.00533. Online ahead of print. J Clin Oncol. 2024. PMID: 39378386
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC.
Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY. Nassar AH, et al. Among authors: gray je. J Thorac Oncol. 2024 Sep 10:S1556-0864(24)02265-2. doi: 10.1016/j.jtho.2024.09.1379. Online ahead of print. J Thorac Oncol. 2024. PMID: 39260522
522 results